Advanced esophagogastric junction cancer with brain, bone and gastric intramural metastases responding to combined modality therapy
- VernacularTitle:Advanced esophagogastric junction cancer with brain, bone and gastric intramural metastases responding to combined modality therapy
- Author:
Takehiro TAKAGI
1
;
Satoshi KOBAYASHI
1
;
Atsushi SEKIMURA
1
;
Kenichi KOMAYA
1
;
Yuji YAMAUCHI
1
;
Akihiro HORI
1
Author Information
- Keywords: esophagogastric junction cancer; gastric intramural metastases; bone metastasis; combined modality therapy
- From:Journal of Rural Medicine 2021;16(3):179-183
- CountryJapan
- Language:English
- Abstract: A 63-year-old man was admitted to our hospital in March 2017 with dysphagia and right homonymous hemianopsia. We diagnosed him with esophagogastric junction cancer (adenocarcinoma) with metastases to the cerebral occipital lobe, bone, and lymph nodes. After one cycle of 5FU + cisplatin (FP), the brain metastasis was resected because of the hemiplegic symptoms he developed. Histology of the resected tissue showed no viable tumor cells. After three cycles of FP, the primary lesion and metastases were resolved. Upper gastrointestinal endoscopy revealed a scar at the primary site. This was considered a complete response (CR). In April 2018, CT revealed a mass at the cardia, which was considered as lymph node metastases with gastric wall invasion. Although two additional cycles of FP were administered for recurrent tumors, the efficacy was progressive. In August 2018, proximal gastrectomy and D1 + lymph node dissection were performed. The pathological diagnosis was gastric intramural metastases and lymph node metastases (ypN1 [2/22]). Weekly paclitaxel therapy was administered for three months after surgery. Two years have passed since the last surgery without recurrence. We report a rare case of esophagogastric junction cancer with brain, bone, and gastric intramural metastases that responded to combined modality therapy.
